Equity Research, Broker Reports, and media content on Santhera Pharmaceuticals Holding AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Santhera Pharmaceuticals Holding AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Santhera Pharmaceuticals Holding AG

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Santhera Pharmaceuticals Holding AG. We currently have 0 research reports from 0 professional analysts.

Date Source Announcement
21Aug18 06:00 GNW Santhera to Report First Half-Year Financial Figures and Provide Corporate Update on September 4, 2018
05Jul18 06:00 GNW Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy
22Jun18 06:00 GNW UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy
12Jun18 06:00 GNW Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON
12Apr18 12:30 GNW Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
05Apr18 06:00 GNW Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy
20Mar18 06:00 GNW Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy
  • Frequency of research reports

     

  • Research reports on

    Santhera Pharmaceuticals Holding AG

  • Providers covering

    Santhera Pharmaceuticals Holding AG